Start
Completion

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

RecruitingRegisteredCTG

Randomised, triple-masked, crossover Phase I study (n=20) comparing oral psilocin (17.5 mg), sublingual psilocin (2.18–4.36 mg), and oral psilocybin (25 mg) in healthy adults with preparatory and integration sessions.

Details

This is a randomized, triple-masked, within-subject crossover study in 20 healthy adults comparing physiological and psychological effects of oral psilocin, sublingual psilocin, and oral psilocybin across multiple supervised dosing sessions.

Participants undergo baseline assessments, preparatory visits with trained facilitators, supervised dosing with clinician safety monitoring, and post-session integration; procedures may be repeated up to three additional times per participant.

Topics:Healthy Volunteers

Registry

Registry linkNCT05317689